ArticleFrontiers in digital health2025
Impact of the use of the ultra-portable digital x-ray with CAD4TB for active case finding for tuberculosis in Nigeria.
Article in Frontiers in digital health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The ultra-portable digital x-ray (UPDX) with computer-aided detection (CAD) is a new technology aimed at bringing tuberculosis (TB) screening innovations to hard-to-reach communities and strengthening the active case-finding (ACF) interventions for TB. As TB control measures remain critical globally and in Nigeria, the country acquired and rolled out 10 UPDX with computer-aided detection (CAD4TB) software in eight states. This study seeks to evaluate the efficiency and impact of the UPDX with CAD4TB for TB case finding in Nigeria. Methods: A retrospective cross-sectional study involving the review of records of individuals 4 years and above who had presented for TB screening during ACF activities conducted using the UPDX with CAD4TB between January 2022 and September 2022. Results: A total of 94,694 subjects aged 4 years and above were screened for TB with an average presumptive TB proportion of 10.84 ± 5.42% and 10% confirmed TB ( Conclusion: We documented the usefulness of UPDX with CAD showing a high TB prevalence and test positivity rate, with significant burden of subclinical TB. This has highlighted the need to scale up its use for ACF for TB and select CAD thresholds for both children and adults.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.